IRAKIMiDs: Protein degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broad activity with durable regressions in MYD88 mutant lymphoma xenografts in vivo
Area of Focus
Oncology
Programs
IRAKIMiD (KT-413)
Indications
MYD88 Tumors
Development Stage
Pre-clinical Data
Share
